Adsorptive cytapheresis in ulcerative colitis: A non-pharmacological therapeutic approach revisited.
adsorptive cytapheresis
efficacy
inflammatory bowel diseases
mechanisms of action
safety
side effects
ulcerative colitis
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
03
09
2023
received:
14
06
2023
accepted:
14
09
2023
pubmed:
3
10
2023
medline:
3
10
2023
entrez:
3
10
2023
Statut:
ppublish
Résumé
Adsorptive cytapheresis proves effective in a proportion of patients affected by ulcerative colitis. Relatively high cost and the need for apheresis facilities, prevented the widespread use of this therapeutic approach. More so following the introduction of anti-TNFα biosimilars which proved both effective and inexpensive. Anti-TNFα agents, however, are burdened by high rate of primary and secondary non-response and prompt switching to new, high-cost biologics, and small molecules. The present review analyzes advantages and disadvantages of adsorptive cytapheresis in the present clinical scenario and suggests its repositioning in the therapeutic workup of selected subgroups of ulcerative colitis patients. The extremely favorable safety profile makes adsorptive cytapheresis a viable therapeutic option in elderly and high-risk UC patients, as well as potential second-line treatment in corticosteroid-dependent patients and poor responders to first-line biologics.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
746-754Informations de copyright
© 2023 The Authors. Journal of Clinical Apheresis published by Wiley Periodicals LLC.
Références
Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NORSWITCH): a 52-week, randomised, doubleblind, non-inferiority trial. Lancet. 2017;389:2304-2316.
Habermalz B, Sauerland S. Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci. 2010;55:1421-1428.
Fukuda Y, Matsui T, Suzuki Y. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J Gastroenterol. 2004;39:1158-1164.
Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives. Clin Exp Gastroenterol. 2021;14:333-342.
Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16:185-196.
Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372-2384.
Wehkamp F, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res. 2018;7:1207.
Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33:987-995.
Savelkoul E, Thomas P, Derikx L, den Broeder N, Römkens T, Hoentjen F. P440 loss of response and dose escalation of infliximab and adalimumab in ulcerative colitis patients: a systematic review and meta-analysis. J Crohns Colitis. 2022;16(Suppl 1):i422-i423.
Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49-54.
Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44:495-507.
Bokemeyer B, Picker N, Wilke T, Rosin L, Patel H. Inadequate response, treatment patterns, health care utilization, and associated costs in patients with ulcerative colitis: retrospective cohort study based on german claims data. Inflamm Bowel Dis. 2022;28:1647-1657.
Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22:4794-4801.
Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155:337-346.
Sáez-González E, Moret I, Alvarez-Sotomayor D, et al. Immunological mechanisms of adsorptive cytapheresis in inflammatory bowel disease. Dig Dis Sci. 2017;62:1417-1425.
Fukuchi T, Kawashima K, Koga H, et al. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis without the use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr. 2022;70:197-204.
Iitzuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refactory ulcerative colitis. World J Gastroenterol. 2021;27:1194-1212.
Saniabadi AR, Hanai H, Fukunaga K, et al. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200.
Fujimori J, Yoshino S, Koiwa M, et al. Improvement in rheumatoid arthritis following application of an extracorporeal granulotrap column, G-1. Rheumatol Int. 1996;15:175-180.
Sawada K, Ohnishi K, Kosaka T, et al. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher. 1997;1:207-211.
Schneider M, Waitz G, Prophet H, Schober HC, Ramlow W. Adsorptive cytapheresis for ulcerative colitis with focus on removing platelets and platelet-aggregates. Ther Apher Dial. 2023;27:452-463.
Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther. 2006;6:453-466.
Hanai H, Iida T, Takeuchi K, et al. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103:1210-1216.
Pai RK, Hartman DJ, Rivers CR, et al. Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18:2510-2517.
Eberhardson M, Marits P, Jones M, et al. Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. Clin Immunol. 2013;149:73-82.
Yokoyama Y, Fukunaga K, Fukuda Y, et al. Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci. 2007;52:2725-2731.
Kashiwagi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci. 2002;47:1334-1341.
Kashiwagi N, Saito F, Maegawa H, Kaneda K. Granulocyte and monocyte adsorptive apheresis induces apoptosis of neutrophils and release of a novel chemoattractant for desensitization of interleukin-8 response - in vitro and in vivo results. Cytokine. 2021;139:155410.
Hanai H, Watanabe F, Yamada M, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70:36-44.
Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis. 2007;39:430-434.
Hanai H, Iida T, Takeuchi K, et al. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multicentre controlled study. Dig Liver Dis. 2008;40:433-440.
Sands B, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400-409.
Domènech E, Panés J, Hinojosa J, et al. Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: a randomized multicentre clinical trial. J Crohns Colitis. 2018;12:687-694.
Dignass A, Akbar A, Baumgart DC, et al. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scand J Gastroenterol. 2018;53:442-448.
Sawada K, Kusugami K, Suzuki Y, et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol. 2005;100:1362-1369.
Kakimoto K, Matsuura M, Fukuchi T, et al. Exploratory study of the effectiveness of granulocyte and monocyte adsorptive apheresis before initiation of steroids in patients with active ulcerative colitis (EXPECT study): a multicenter prospective clinical trial. Crohns Colitis 360. 2020;2:otaa073.
Yoshino T, Nakase H, Minami N, et al. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis. 2014;46:219-226.
Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004;36:811-817.
Song A, Jiang H, Guo L, Wu S. The combined efficacy of Adalimumab with GMA method on the treatment of ulcerative colitis and repair of intestinal mucosal lesion. Am J Transl Res. 2021;13:5156-5164.
Tanida S, Ozeki K, Kanno T, et al. Combination therapy with ustekinumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis. J Clin Med Res. 2021;13:510-514.
Yokoyama Y, Sawada K, Aoyama N, et al. Efficacy of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease showing lost response to infliximab. J Crohns Colitis. 2020;14:1264-1273.
Rodriguez-Lago I, Sempere L, Gutiérrez A, et al. Granulocyte monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. Scand J Gastroenterol. 2019;54:459-464.
Rodriguez-Lago I, Benitez JM, Sempere L, et al. The combination of granulocyte-monocyte apheresis and vedolizumab: a new treatment option for ulcerative colitis? J Clin Apher. 2019;34:680-685.
Nakamura M, Yamamura T, Maeda K, et al. Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis. Intern Med. 2020;59:3009-3014.
Iizuka M, Etou K, Sagara S. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. World J Gastroenterol. 2022;28:4959-4972.
Komoto S, Matsuoka K, Kobayashi T, et al. Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: the impact in steroid-free elderly patients. J Gastroenterol Hepatol. 2018;33:1485-1491.
Motoya S, Tanaka H, Shibuya T, et al. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study. BMC Gastroenterol. 2019;19:196.
Shibuya T, Nomura O, Nomura K, et al. Effectiveness of cytapheresis for ulcerative colitis in special situations: delayed onset of optimum efficacy in elderly patients. Digestion. 2020;101:46-52.
Ruuska T, Küster P, Grahnquist L, Lindgren F, Wewew AV. Efficacy and safety of granulocyte, monocyte/macrophage adsorptive in pediatric ulcerative colitis. World J Gastroenterol. 2016;22:4389-4396.
Rolandsdotter H, Eberhardson M, Fagerberg UL, Finkel Y. Granulocyte and monocyte apheresis for induction of remission in children with new-onset inflammatory bowel colitis. J Pediatr Gastroenterol Nutr. 2018;66:84-89.
D'Ovidio V, Meo D, Gozer M, Bazuro ME, Vernia P. Ulcerative colitis and granulocyte-monocyte-apheresis: safety and efficacy of maintenance therapy during pregnancy. J Clin Apher. 2015;30:55-57.
Takahashi H, Sugawara K, Sugimura M, et al. Flare up of ulcerative colitis during pregnancy treated by adsorptive granulocyte and monocyte apheresis: therapeutic outcomes in three pregnant patients. Arch Gynecol Obstet. 2013;288:341-347.
Yamamoto T, Iida T, Ikeya K, et al. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulo-monocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9:170.
Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S. Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther. 2010;31:1286-1295.
Nishioka C, Aoyama N, Maekawa S, et al. Leukocytapheresis therapy for steroid naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol. 2005;20:1567-1571.
Yokoyama Y, Matsuoka K, Kobayashi T, et al. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice. J Crohns Colitis. 2014;8:981-991.
Cabriada JL, Domenech L, Ibargoyen N, et al. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol. 2012;47:359-365.
Code of Federal Regulations. Title 21, Volume 5; 21CFR312.32.
Ishiguro Y, Ohomori T, Umemura K, Iizuka M. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: a multicenter cohort study. Ther Apher Dial. 2021;25:502-512.
Sawada K, Ohdo M, Ino T, et al. Safety and tolerability of nafamostat mesilate and heparin as anticoagulants in leukocytapheresis for ulcerative colitis: post hoc analysis of a large-scale, prospective, observational study. Ther Apher Dial. 2016;20:197-204.
Hibi T, Sameshima Y, Sekiguchi Y, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis. 2009;41:570-577.
Bresci G, Parisi G, Bertoni M, Mazzoni A, Scatena F, Capria A. Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: our experience with a prospective study. World J Gastroenterol. 2006;14:2201-2204.
Dignass A, Akbar A, Hart A, et al. Safety and efficacy of granulocyte/monocyte apheresis in steroid-dependent active ulcerative colitis with insufficient response or intolerance to immunosuppressants and/or biologics [the ART trial]: 12-week interim results. J Crohns Colitis. 2016;10:812-820.
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraiashi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41-47.
Scrivo B, Vitello A, Cappello M. Response to the combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous anti-TNF alfa failure. Dig Liver Dis. 2018;50:1103-1104.
Naganuma M, Yokoyama Y, Motoya S, et al. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. J Gastroenterol. 2020;55:390-400.
Yanagisawa K, Murakami M, Kondo Y, et al. Efficacy and safety of adsorptive granulocyte and monocyte apheresis in elderly and pregnant patients with ulcerative colitis. Ther Apher Dial. 2019;23:217-223.
Fukunaga K, Yokoyama Y, Kamokozuru K, et al. Granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial. Gut Liver. 2012;6:427-433.
Shibuya T, Haga K, Kamei M, et al. Successful remission of ulcerative colitis flare-up during pregnancy with adsorptive granulomonocytapheresis plus tacrolimus. Intest Res. 2018;16:484-488.
Iida T, Ikeya K, Kato M, et al. Adsorptive depletion of myeloid lineage leucocytes as remission induction therapy in patients with ulcerative colitis after failure of first-line medications: results from a three-year real world, clinical practice. Digestion. 2017;96:119-126.
Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004;49:565-571.
Nishise S, Takeda Y, Nara H, et al. Adsorption of soluble immunoglobulin-type adhesion molecules to cellulose acetate beads. Ther Apher Dial. 2018;22:261-265.
Yang H, Li B, Guo Q, et al. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;55:764-777.
Yoshino T, Nakase H, Matsuura M, et al. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants. Digestion. 2011;84:3-9.
Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing Committee of the American Society for Apheresis: the ninth special issue. J Clin Apher. 2023;38:77-278.
Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2-17.